These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 20637457)

  • 21. Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in vitro fertilization/embryo transfer programs.
    Orvieto R; Kruchkovich J; Rabinson J; Zohav E; Anteby EY; Meltcer S
    Fertil Steril; 2008 Jul; 90(1):228-30. PubMed ID: 17681292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is a premature rise in luteinizing hormone in the absence of increased progesterone levels detrimental to pregnancy outcome in GnRH antagonist in vitro fertilization cycles.
    Dovey S; McIntyre K; Jacobson D; Catov J; Wakim A
    Fertil Steril; 2011 Sep; 96(3):585-9. PubMed ID: 21774931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of early versus late initiation of GnRH antagonist co-treatment for controlled ovarian stimulation in IVF: a randomized controlled trial.
    Hamdine O; Macklon NS; Eijkemans MJ; Laven JS; Cohlen BJ; Verhoeff A; van Dop PA; Bernardus RE; Lambalk CB; Oosterhuis GJ; Holleboom CA; van den Dool-Maasland GC; Verburg HJ; van der Heijden PF; Blankhart A; Fauser BC; Broekmans FJ;
    Hum Reprod; 2013 Dec; 28(12):3227-35. PubMed ID: 24129613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols.
    Farhi J; Ben-Haroush A; Lande Y; Sapir O; Pinkas H; Fisch B
    Fertil Steril; 2009 Feb; 91(2):377-82. PubMed ID: 18321490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of delayed initiation of gonadotropin-releasing hormone antagonist in a flexible protocol on in vitro fertilization outcome.
    Tannus S; Weissman A; Boaz M; Horowitz E; Ravhon A; Golan A; Levran D
    Fertil Steril; 2013 Mar; 99(3):725-30. PubMed ID: 23219008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF.
    Lainas T; Zorzovilis J; Petsas G; Stavropoulou G; Cazlaris H; Daskalaki V; Lainas G; Alexopoulou E
    Hum Reprod; 2005 Sep; 20(9):2426-33. PubMed ID: 15946995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fixed versus flexible antagonist protocol in women with predicted high ovarian response except PCOS: a randomized controlled trial.
    Luo X; Pei L; Li F; Li C; Huang G; Ye H
    BMC Pregnancy Childbirth; 2021 May; 21(1):348. PubMed ID: 33934703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synchronization of ovarian stimulation with follicle wave emergence in patients undergoing in vitro fertilization with a prior suboptimal response: a randomized, controlled trial.
    Baerwald A; Anderson P; Yuzpe A; Case A; Fluker M
    Fertil Steril; 2012 Oct; 98(4):881-7.e1-2. PubMed ID: 22819187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation.
    Christin-Maitre S; Olivennes F; Dubourdieu S; Chabbert-Buffet N; Charbonnel B; Frydman R; Bouchard P
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):721-6. PubMed ID: 10848876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH.
    Levi-Setti PE; Cavagna M; Bulletti C
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):212-6. PubMed ID: 16377062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
    Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The addition of GnRH antagonists in intrauterine insemination cycles: a pilot study.
    Graziano A; Caserta D; Piva I; Lo Monte G; Bordi G; Martini F; Tognon M; Marci R
    Eur Rev Med Pharmacol Sci; 2013 Jun; 17(12):1604-10. PubMed ID: 23832726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Menstrual cycle synchronization, ovarian stimulation, and in vitro fertilization in olive baboons (Papio anubis): a prospective randomized study.
    Nyachieo A; Spiessens C; Chai DC; Mwenda JM; D'Hooghe TM
    Fertil Steril; 2009 Feb; 91(2):602-10. PubMed ID: 18328482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GnRH antagonists in ovarian stimulation for IVF.
    Tarlatzis BC; Fauser BC; Kolibianakis EM; Diedrich K; Rombauts L; Devroey P
    Hum Reprod Update; 2006; 12(4):333-40. PubMed ID: 16567347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
    Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Follicular phase endocrine characteristics during ovarian stimulation and GnRH antagonist cotreatment for IVF: RCT comparing recFSH initiated on cycle day 2 or 5.
    Blockeel C; Sterrenburg MD; Broekmans FJ; Eijkemans MJ; Smitz J; Devroey P; Fauser BC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):1122-8. PubMed ID: 21307142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).
    Olivennes F; Belaisch-Allart J; Emperaire JC; Dechaud H; Alvarez S; Moreau L; Nicollet B; Zorn JR; Bouchard P; Frydman R
    Fertil Steril; 2000 Feb; 73(2):314-20. PubMed ID: 10685535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro fertilization outcomes in patients experiencing a premature rise in luteinizing hormone during a gonadotropin-releasing hormone antagonist cycle.
    Kummer NE; Weitzman VN; Benadiva CA; Schmidt DW; Engmann LL; Nulsen JC
    Fertil Steril; 2011 Jun; 95(8):2592-4. PubMed ID: 21292260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.